Abstract
This study demonstrates that dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, impairs working memory of conscious behaving monkeys. In addition, acute and chronic MK-801 produces different effects on D1 and D2 receptor binding in prefrontal cortex (PFC). Extrastriatal neocortical receptor D1 (D1R) and D2 (D2R) binding were assayed by [11C]NNC112 and [11C]FLB457, respectively, using high-specific radioactivity and a specially designed monkey positron emission tomograph (PET). Acute single dose (0.03, 0.1, and 0.3 mg/kg) i.v. administration of MK-801 resulted in dose-related impairment of working memory performance of an oculomotor delayed response (ODR) task. There was no impairment of performance of a visually guided saccade (VGS) task with low doses of 0.03 and 0.1, but it was depressed with 0.3 mg/kg. Chronic daily MK-801 (0.03 mg/kg, i.m., b.i.d. for 13 days) induced impaired ODR task performance with no effect on the VGS task. Although acute single doses of MK-801 caused no significant changes in [11C]NNC112 binding to PFC D1R, chronic daily treatment increased binding about 14% (P<.05). Acute MK-801 dose-dependently decreased [11C]FLB457 binding about 35% (P<.01) to PFC D2R; chronic treatment had no significant effect. Microdialysis analyses demonstrated that acute single doses of MK-801 (0.03 and 0.1 mg/kg) increased extracellular glutamate and dopamine (DA) levels in PFC. Chronic MK-801 gradually lowered glutamate and DA levels in PFC. The results demonstrate in conscious, unanesthetized primates that MK-801 induces impairment of PFC function, as measured by working memory performance. Furthermore, in response to lowered levels of DA in PFC, D1R binding is increased, whereas D2R binding is not.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y et al (2002). Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22: 3708–3719.
Bowers MB, Morton JB (1994). Regional brain catecholamines and metabolites following THC, PCP and MK-801. Prog Neuropsychopharmacol Biol Psychiatry 18: 961–964.
Brozoski T, Brown R, Rosvold H, Goldman P (1979). Cognitive deficits produced by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205: 929–932.
Bunney BG, Bunney Jr WE, Carlsson A (1995). Schizophrenia and glutamate. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press Ltd: New York. pp 1205–1214.
Carlezon Jr WA, Wise RA (1996). Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci 16: 1332–3122.
Carlsson A, Hanson LO, Waters N, Carlsson ML (1997). Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 61: 75–94.
Carter CJ, L'Hereux, Scatton B (1988). Differential control by N-methyl-D-aspartate and kainate of striatal dopamine release in vivo: a trans-striatal dialysis study. J Neurochem 51: 462–468.
Cosgrove J, Newell TG (1991). Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 47: 159–169.
Creese I, Burt DR, Snyder SH (1975). Dopamine receptor binding: differentiation of agonist and antagonist states with [3H]dopamine and [3H]haloperidol. Life Sci 17: 993–1002.
Deutch AY (1992). The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 36: 61–89.
Deutch AY, Tam SY, Freeman AS, Bowers MB, Roth RH (1987). Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Eur J Pharmacol 134: 257–264.
Doherty JD, Simonovic M, So R, Meltzer HY (1980). The effect of phencyclidine on dopamine synthesis and metabolism in rat striatum. Eur J Pharmacol 65: 139–149.
Domino EF, Mirzoyan D, Tsukada H (2004). NMDA antagonists as drug models of schizophrenia: a surprising link to tobacco smoking. Prog Neuropsychopharmacol Biol Psychiat 28: 801–811.
During MJ, Bean AJ, Roth RH (1987). Effects of CNS stimulation on the in vivo release of the colocalized transmitters, dopamine and neurotensin, from rat prefrontal cortex. Neurosci Lett 140: 129–133.
Fagg GE (1987). Phencyclidine and related drugs bind to the activated N-methyl-D-aspartate receptor-channels complex in rat brain membranes. Neurosci Lett 76: 221–227.
Fessler RG, Sturgeon RD, Meltzer HY (1979). Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesions of nucleus accumbens: comparison to other psychomotor stimulants. Psychopharmacology 82: 83–88.
Goldman-Rakic PS (1987). Circuitry of prefrontal cortex and the regulation of behavior by representational knowledge. In: Plum F, Mountcasle V (eds). Handbook of Physiology. American Physiological Society: Bethesda, MD. pp 373–412.
Goldman-Rakic PS, Brown RM (1981). Regional changes of monoamines in cerebral cortex and subcortical structure of aging rhesus monkeys. Neuroscience 6: 177–187.
Grace AA (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsibility: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1–24.
Grunze HCR, Rainnie DG, Hasselmo ME, Barkai E, Heam EF, McCarley RW et al (1994). NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16: 2034–2043.
Hall H, Farde L, Sedvall G (1988). Human dopamine receptor subtypes—in vitro binding analysis using 3H-SCH23390 and 3H-raclopride. J Neural Transm 73: 7–21.
Halldin C, Farde L, Högberg T, Mohell N, Hall H, Suhara T et al (1995). Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36: 1275–1281.
Halldin C, Foget C, Chou Y-H, Karlsson P, Swahn C-G, Sandell J et al (1998). Carbon-11-NNC112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med 39: 2061–2068.
Hondo H, Yonezawa Y, Nakahara T, Nakamura K, Hirano M, Uchimura H et al (1994). Effects of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res 633: 337–342.
Inoue M, Mikami A, Ando I, Tsukada H (2004). Functional brain mapping of the macaque related to spatial working memory as revealed by PET. Cereb Cortex 14: 106–119.
Javitt DC, Zukin SR (1991). Recent advances in phencyclidine model of schizophrenia. Am J Psychiat 148: 1301–1308.
Jentsch JD, Elsworth JD, Redmond Jr DE, Roth RH (1997a). Phencyclidine increases forebrain monoamine metabolism in rats and monkey: modulation by the isomers of HA966. J Neurosci 17: 1769–1775.
Jentsch JD, Redmond Jr DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997b). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277: 953–955.
Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201–225.
Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997c). Subchronic phencyclidine administration reduces mesofrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropharmacology 17: 92–99.
Johnson KM, Jones SM (1990). Neuropharmacology of phencyclidine: a therapeutic potential. Ann Rev Pharmacol Toxicol 30: 707–750.
Krebs MO, Desce JM, Kemel ML, Gauchy C, Godeheu G, Cheramy A et al (1991). Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J Neurochem 56: 81–85.
Krystal JH, Abi-Dargham A, Larulle M, Moghaddam B (2004). Pharmacological models of psychoses(Chapter 21). In: Charney DS, Nestler (eds). Neurobiology of Mental Illness, 2nd edn. Oxford University Press: New York. pp 287–298.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptional, cognitive and neuroendocrine response. Arch Gen Psychiatry 51: 199–214.
Lammertsma A, Hume S (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153–158.
Lidow MS, Goldman-Rakic PS, Rakic P, Innis RB (1989). Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride. Proc Natl Acad Sci USA 86: 6412–6416.
Lodge D, Berry SC, Burton NR (1983). Arylcyclohexylamines selectively reduce excitation of mammalian nerones by aspartate-like amino acids. In: Kamenka JM, Domino EF, Geneste P (eds). Phencyclidine and Related Arylcyclohexylamines: Present and Future Applications. NPP Books: Ann Arbor. pp 595–616.
Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R (1959). Study of a new schizophrenomimetic drug—Sernyl. Arch Neurol Psychiat 81: 363–369.
Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF (1962). Model psychoses and schizophrenia. Am J Psychiatry 118: 61–67.
Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301–307.
Meador-Woodruff JH, Kleinman JE (2002). Neurochemistry of schizophrenia: glutamatergic abnormalities. In: David KL, Charney D, Coyle JT, Nemeroff C (eds). The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 717–728.
Mizoguchi K, Yuzurihara M, Ishige A, Sasaki H, Chui DH, Tabira T (2000). Chronic stress induces impairment of spatial working memory because of prefrontal dopaminergic dysfunction. J Neurosci 20: 1568–1574.
Morari M, O'Connor T, Ungerstedt U, Fuxe K (1993). N-methyl-D-aspartic acid differentially regulates extracellular dopamine, GABA and glutamate levels in the dorsolateral neostriatum of the halothane-anesthetized rat: an in vivo microdialysis study. J Neurochem 60: 1884–1893.
Murphy BL, Arnsten AFT, Goldman-Rakic PS, Roth RH (1996a). Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 93: 1325–1329.
Murphy BL, Arnsten AFT, Jentsch JD, Roth RH (1996b). Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment. J Neurosci 16: 7768–7775.
Murray TF, Horita A (1978). Phencyclidine-induced stereotyped behavior in rats: dose–response effects and antagonism by neuroleptics. Life Sci 24: 2217–2226.
Okauchi T, Suhara T, Maeda J, Kawabe K, Ohbayashi S, Suzuki K (2001). Effect of endogenous dopamine on extrastriatal [11C]FLB457 binding measured by PET. Synapse 41: 87–95.
Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O et al (1997). Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 386: 634–636.
Oye N, Paulsen O, Maurset A (1992). Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260: 1209–1213.
Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL (1990). Selective activation of dopaminergic pathways in the mesocortex by compounds that act at phencyclidine (PCP) binding site: tentative evidence for PCP recognition sites not coupled to N-methyl-D-aspartate (NMDA) receptors. Neuropharmacology 29: 225–230.
Robbins TW (1990). The case for frontostriatal dysfunction in schizophrenia. Schizophr Bull 16: 391–402.
Roberts PJ, Anderson SD (1979). Stimulatory effect of L-glutamate and related amino acids on [3H]dopamine release from rat striatum: an in vitro model for glutamate actions. J Neurochem 32: 1539–1545.
Sawaguchi T, Goldman-Rakic PS (1991). D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251: 947–950.
Shi W-X, Zhang X-X (2003). Dendritic glutamate-induced bursting in the prefrontal cortex: further characterization and effects of phencyclidine. J Pharmacol Exper Ther 305: 680–687.
Smiley JF, Levey A, Ciliax B, Goldman-Rakic PS (1994). D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. Proc Natl Acad Sci USA 91: 5720–5724.
Snyder SH (1980). Phencyclidine. Nature 285: 355–358.
Sorg BA, Kalivas PW (1993). Effects of cocaine and footshock stress on extracellular dopamine levels in the medial prefrontal cortex. Neuroscience 53: 695–703.
Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichiyama T et al (2002). Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59: 25–30.
Thomson AM, West DC, Lodge D (1985). An N-methyl-D-aspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature 313: 479–481.
Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T (2000a). Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: PET studies with microdialysis in the conscious monkey brain. J Neurosci 20: 7067–7073.
Tsukada H, Harada N, Nishiyama S, Ohba H, Sato K, Fukumoto D et al (2000b). Ketamine decreased striatal [11C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multi-parametric PET studies combined with microdialysis analysis. Synapse 37: 95–103.
Tsukada H, Harada N, Ohba H, Nishiyama S, Kakiuchi T (2001a). Facilitation of dopaminergic neural transmission does not affect [11C]SCH23390 binding to the striatal D1 dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D1 receptors: PET studies in the conscious monkey brain. Synapse 42: 258–265.
Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF (2002). Comparative effects of methamphetamine and nicotine on the striatal [11C]raclopride binding in unanesthetized monkeys. Synapse 45: 207–212.
Tsukada H, Nishiyama S, Fukumoto D, Ohba H, Sato K, Kakiuchi T (2004). Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse 52: 1–10.
Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N (1999a). Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride? PET studies combined with microdialysis in conscious monkeys. Brain Res 841: 160–169.
Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N (2001b). Ketamine alters the availability of striatal dopamine transporter as measured by [11C]β-CFT and [11C]β-CIT-FE in the monkey brain. Synapse 42: 273–280.
Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N et al (1999b). Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res 849: 85–96.
Verma A, Moghaddam B (1996). NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16: 373–379.
Watanabe M, Okada H, Shimizu K, Omura T, Yoshikawa E, Kosugi T et al (1997). A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci 44: 1277–1282.
Weinberger DR, Berman KF, Zee RF (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia, I: regional cerebral blood flow evidence. Arch Gen Psychiatry 43: 114–124.
Yonezawa Y, Kuroki T, Kawahara T, Tashiro N, Uchimura H (1998). Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur J Pharmacol 341: 45–56.
Youngren KD, Daly DA, Moghaddam B (1993). Distinct action of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens. J Pharmacol Exp Ther 264: 289–293.
Acknowledgements
We are grateful to Ichiro Ando and Mitsuru Suzuki for their technical assistance. This work was supported in part by Grant-in-Aid for Creative Scientific Research of Japan Society for the Promotion of Science, and CREST, JST.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsukada, H., Nishiyama, S., Fukumoto, D. et al. Chronic NMDA Antagonism Impairs Working Memory, Decreases Extracellular Dopamine, and Increases D1 Receptor Binding in Prefrontal Cortex of Conscious Monkeys. Neuropsychopharmacol 30, 1861–1869 (2005). https://doi.org/10.1038/sj.npp.1300732
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300732
Keywords
This article is cited by
-
Pharmacogenetic activation of parvalbumin interneurons in the prefrontal cortex rescues cognitive deficits induced by adolescent MK801 administration
Neuropsychopharmacology (2023)
-
MK-801 and cognitive functions: Investigating the behavioral effects of a non-competitive NMDA receptor antagonist
Psychopharmacology (2023)
-
In vivo glucose metabolism and glutamate levels in mGluR5 knockout mice: a multimodal neuroimaging study using [18F]FDG microPET and MRS
EJNMMI Research (2020)
-
Chronic phencyclidine treatment impairs spatial working memory in rhesus monkeys
Psychopharmacology (2019)
-
Molecular Imaging of mGluR5 Availability with [11C]ABP68 in Glutaminase Heterozygous Mice
Cellular and Molecular Neurobiology (2019)
